Published in Osteoporos Int on August 15, 2007
Green tea and bone metabolism. Nutr Res (2009) 1.12
Results of observational studies: analysis of findings from the Nurses' Health Study. PLoS One (2014) 0.91
'Biasing' the parathyroid hormone receptor: a novel anabolic approach to increasing bone mass? Br J Pharmacol (2011) 0.88
Bone mineralization: from tissue to crystal in normal and pathological contexts. Osteoporos Int (2012) 0.85
Glucocorticoid-induced osteoporosis: treatment update and review. Ther Adv Musculoskelet Dis (2009) 0.82
Clinical and radiographic evaluation of effect of risedronate 5 mg as an adjunct to treatment of chronic periodontitis in postmenopausal women (12-month study). Osteoporos Int (2016) 0.81
Fragility of Bone Material Controlled by Internal Interfaces. Calcif Tissue Int (2015) 0.79
Effects of life-long fluoride intake on bone measures of adolescents: a prospective cohort study. J Dent Res (2014) 0.77
Overweight adolescents with type 2 diabetes have significantly higher lipoprotein abnormalities than those with type 1 diabetes. Diabetes Res Clin Pract (2016) 0.75
Bone: Sequential osteoporosis treatment--the order of things. Nat Rev Endocrinol (2015) 0.75
Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials (1996) 64.38
The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol (1997) 9.01
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med (2004) 6.55
Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med (1990) 5.49
Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. Comparison with conventional therapy. N Engl J Med (1982) 3.77
Improved tests for a random effects meta-regression with a single covariate. Stat Med (2003) 2.26
The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial. Ann Intern Med (1998) 2.14
Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females. Eur J Clin Invest (1980) 2.04
Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk--a meta-analysis. Osteoporos Int (2006) 1.79
Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial. Ann Intern Med (1995) 1.72
Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis. Osteoporos Int (2000) 1.59
Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet (1988) 1.50
Effect of combined therapy with sodium fluoride, vitamin D and calcium in osteoporosis. Am J Med (1972) 1.50
Treatment of osteoporosis with fluoride, calcium, and vitamin D. Orthop Clin North Am (1981) 1.29
A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporos Int (1991) 1.23
Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev (2006) 1.19
Fluoride for treating postmenopausal osteoporosis. Cochrane Database Syst Rev (2000) 1.04
The effect of fluoride and calcium on spinal bone mineral content: a controlled, prospective (3 years) study. Calcif Tissue Int (1987) 0.96
A longitudinal study of markers of bone turnover in Graves' disease and their value in predicting bone mineral density. J Clin Endocrinol Metab (1997) 0.93
Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy. Osteoporos Int (1998) 0.92
Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study. J Clin Endocrinol Metab (1999) 0.90
Effect of sodium fluoride, calcium, phosphate, and vitamin D2 on trabecular bone balance and remodeling in osteoporotics. Bone (1985) 0.86
Fluoride stimulates [3H]thymidine incorporation and alkaline phosphatase production by human osteoblasts. Metabolism (1990) 0.85
The effect of fluoride contents in fluoridated hydroxyapatite on osteoblast behavior. Acta Biomater (2005) 0.84
Trabecular stress fractures during fluoride therapy for osteoporosis. Skeletal Radiol (1985) 0.84
Avoidance of vertebral fractures in men with idiopathic osteoporosis by a three year therapy with calcium and low-dose intermittent monofluorophosphate. Osteoporos Int (1998) 0.83
In corticosteroid-treated respiratory diseases, monofluorophosphate increases lumbar bone density: a double-masked randomized study. Osteoporos Int (1996) 0.82
Therapy of established postmenopausal osteoporosis with monofluorophosphate plus calcium: dose-related effects on bone density and fracture rate. Osteoporos Int (1999) 0.82
Effects of fluoride on human bone cells in vitro: differences in responsiveness between stromal osteoblast precursors and mature osteoblasts. Eur J Endocrinol (1994) 0.82
Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis? Ann Rheum Dis (1997) 0.81
Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate. Aliment Pharmacol Ther (2003) 0.81
Increase of bone mineral density with sodium fluoride in patients with Crohn's disease. Eur J Gastroenterol Hepatol (2000) 0.80
Effect of sodium fluoride on the prevention of corticosteroid-induced osteoporosis. Osteoporos Int (1997) 0.79
Effect of disodium monofluorophosphate, calcium and vitamin D supplementation on bone mineral density in patients chronically treated with glucocorticosteroids: a prospective, randomized, double-blind study. Miner Electrolyte Metab (1996) 0.79
Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years. Gastroenterology (1997) 0.78
Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride. Aliment Pharmacol Ther (2002) 0.78
Stress fractures of the lower limbs in osteoporotic patients treated with fluoride. J Bone Miner Res (1990) 0.78
Treatment of postmenopausal vertebral osteopenia with monofluorophospate: a long-term calcium-controlled study. Osteoporos Int (1995) 0.78
Cyclical etidronate versus sodium fluoride in established postmenopausal osteoporosis: a randomized 3 year trial. Bone (2000) 0.77
Relief of osteoporotic backache with fluoride, calcium, and calciferol. Acta Med Scand (1981) 0.77
Efficacy of etidronate and sequential monofluorophosphate in severe postmenopausal osteoporosis: a pilot study. Rheumatol Int (2005) 0.75
Monofluorophosphate increases lumbar bone density in osteopenic patients: a double-masked randomized study. Osteoporos Int (1995) 0.75
Fluoride therapy in prevention of rheumatoid arthritis induced bone loss. J Rheumatol (1997) 0.75
Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology (2001) 3.00
Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J Bone Miner Res (2001) 2.89
Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab (2009) 2.69
Increased mortality in patients with a hip fracture-effect of pre-morbid conditions and post-fracture complications. Osteoporos Int (2007) 2.46
Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int (2006) 2.33
Complement facilitates early prion pathogenesis. Nat Med (2001) 2.30
Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension (1994) 2.28
Plasma concentrations of 25-hydroxy-vitamin D and 1,25-dihydroxy-vitamin D are related to the phenotype of Gc (vitamin D-binding protein): a cross-sectional study on 595 early postmenopausal women. Calcif Tissue Int (2005) 2.23
Captured by art. Science (2001) 2.21
A reverse J-shaped association of all-cause mortality with serum 25-hydroxyvitamin D in general practice: the CopD study. J Clin Endocrinol Metab (2012) 2.16
Fracture rates and risk factors for fractures in patients with spinal cord injury. Spinal Cord (1998) 2.07
The influence of smoking on vitamin D status and calcium metabolism. Eur J Clin Nutr (1999) 2.03
Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk--a meta-analysis. Osteoporos Int (2006) 1.79
Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia (2005) 1.79
Global vitamin D levels in relation to age, gender, skin pigmentation and latitude: an ecologic meta-regression analysis. Osteoporos Int (2008) 1.78
Fracture risk associated with the use of morphine and opiates. J Intern Med (2006) 1.71
Transmission of scrapie by steel-surface-bound prions. Mol Med (2001) 1.63
Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. J Bone Miner Res (1993) 1.57
Myopathy in bone loss of ageing: improvement by treatment with 1 alpha-hydroxycholecalciferol and calcium. Clin Sci (Lond) (1979) 1.49
Stereological considerations concerning the measurement of individual osteoid seams and resorption cavities. Bone Miner (1994) 1.47
Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ (2000) 1.47
Statins decrease bone turnover in postmenopausal women: a cross-sectional study. Eur J Clin Invest (2002) 1.46
Determinants of vitamin D status in a general population of Danish adults. Bone (2011) 1.45
Autosomal dominant osteopetrosis. Clin Orthop Relat Res (1993) 1.44
Isoforms of nitric oxide synthase. Properties, cellular distribution and expressional control. Biochem Pharmacol (1995) 1.42
Familial isolated primary hyperparathyroidism. Clin Endocrinol (Oxf) (1994) 1.42
Stroke in relation to use of raloxifene and other drugs against osteoporosis. Osteoporos Int (2010) 1.42
Clopidogrel and the risk of osteoporotic fractures: a nationwide cohort study. J Intern Med (2012) 1.41
Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex. Thromb Haemost (1995) 1.41
Polymorphisms of muscle genes are associated with bone mass and incident osteoporotic fractures in Caucasians. Calcif Tissue Int (2013) 1.40
[Costs of different intervention strategies to prevent hip fractures]. Ugeskr Laeger (1999) 1.39
Efficacy of wheat germ lectin-precipitated alkaline phosphatase in serum as an estimator of bone mineralization rate: comparison to serum total alkaline phosphatase and serum bone Gla-protein. Calcif Tissue Int (1989) 1.39
Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int (2006) 1.39
Changing incidence and residual lifetime risk of common osteoporosis-related fractures. Osteoporos Int (1993) 1.39
Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut (2000) 1.33
Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin Endocrinol (Oxf) (2005) 1.30
Vitamin D and its binding protein Gc: long-term variability in peri- and postmenopausal women with and without hormone replacement therapy. Scand J Clin Lab Invest (2006) 1.29
The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a cross sectional study. Respir Med (2006) 1.29
The effect of single oral doses of prednisone on the circadian rhythm of serum osteocalcin in normal subjects. J Clin Endocrinol Metab (1988) 1.29
Fracture risk in patients treated for hyperthyroidism. Thyroid (2000) 1.25
Sex differences in age-related changes in vertebral body size, density and biomechanical competence in normal individuals. Bone (1990) 1.23
Radial and humeral fractures as predictors of subsequent hip, radial or humeral fractures in women, and their seasonal variation. Osteoporos Int (1993) 1.22
Lumbar vertebral body compressive strength evaluated by dual-energy X-ray absorptiometry, quantitative computed tomography, and ashing. Bone (1999) 1.22
Age- and sex-related changes in iliac cortical bone mass and remodeling. Bone (1994) 1.19
Parathyroid hormone and bone healing. Calcif Tissue Int (2010) 1.18
Fractures in patients with primary idiopathic hypothyroidism. Thyroid (2000) 1.17
Biomechanical competence of vertebral trabecular bone in relation to ash density and age in normal individuals. Bone (1987) 1.17
Normal vertebral body size and compressive strength: relations to age and to vertebral and iliac trabecular bone compressive strength. Bone (1986) 1.16
Histomorphometric analysis of normal bone from the iliac crest. Acta Pathol Microbiol Scand A (1978) 1.16
Vitamin D insufficiency in Greenlanders on a westernized fare: ethnic differences in calcitropic hormones between Greenlanders and Danes. Calcif Tissue Int (2003) 1.14
Reconstruction of the formative site in iliac trabecular bone in 20 normal individuals employing a kinetic model for matrix and mineral apposition. Metab Bone Dis Relat Res (1984) 1.14
Fracture risk is increased in epilepsy. Acta Neurol Scand (1999) 1.13
Apoptosis of macrophages and T cells in tuberculosis associated caseous necrosis. J Pathol (2000) 1.12
Tetracycline double-labeling of iliac trabecular bone in 41 normal adults. Calcif Tissue Res (1978) 1.12
Calcium-sensing receptor stimulates PTHrP release by pathways dependent on PKC, p38 MAPK, JNK, and ERK1/2 in H-500 cells. Am J Physiol Endocrinol Metab (2003) 1.12
Age-related changes in the biochemical properties of human cancellous bone collagen: relationship to bone strength. Calcif Tissue Int (1999) 1.12
Reduced concentration of collagen reducible cross links in human trabecular bone with respect to age and osteoporosis. Bone (1996) 1.11
New diarylmethylpiperazines as potent and selective nonpeptidic delta opioid receptor agonists with increased In vitro metabolic stability. J Med Chem (2000) 1.11
Missing observations in bone histomorphometry on osteoporosis: implications and suggestions for an approach. Bone (1999) 1.10
Efficient lymphoreticular prion propagation requires PrP(c) in stromal and hematopoietic cells. J Virol (2001) 1.10
Trabecular bone remodeling and balance in primary hyperparathyroidism. Bone (1986) 1.10
Effects of 25OHD concentrations on chances of pregnancy and pregnancy outcomes: a cohort study in healthy Danish women. Eur J Clin Nutr (2012) 1.09
Effects of paracetamol, non-steroidal anti-inflammatory drugs, acetylsalicylic acid, and opioids on bone mineral density and risk of fracture: results of the Danish Osteoporosis Prevention Study (DOPS). Osteoporos Int (2011) 1.08
Assessment of bone remodeling using biochemical indicators of type I collagen synthesis and degradation: relation to calcium kinetics. Bone Miner (1994) 1.07
A randomized study on the effects of estrogen/gestagen or high dose oral calcium on trabecular bone remodeling in postmenopausal osteoporosis. Bone (1989) 1.06
Fracture risk associated with use of nonsteroidal anti-inflammatory drugs, acetylsalicylic acid, and acetaminophen and the effects of rheumatoid arthritis and osteoarthritis. Calcif Tissue Int (2006) 1.06
Reduced relative risk of fractures among users of lithium. Calcif Tissue Int (2005) 1.05
An evaluation of the quantitative parameters applied in bone histology. Acta Pathol Microbiol Scand A (1978) 1.02
Hormone replacement therapy dissociates fat mass and bone mass, and tends to reduce weight gain in early postmenopausal women: a randomized controlled 5-year clinical trial of the Danish Osteoporosis Prevention Study. J Bone Miner Res (2003) 1.02
Low serum levels of 1.25-dihydroxyvitamin D and histomorphometric evidence of osteomalacia after jejunoileal bypass for obesity. Gut (1980) 1.01
Ultrastructural investigations of bone resorptive cells in two types of autosomal dominant osteopetrosis. Bone (1994) 1.00
Bone mineral density in Klinefelter syndrome is reduced and primarily determined by muscle strength and resorptive markers, but not directly by testosterone. Osteoporos Int (2010) 0.99
Correlation between the compressive strength of iliac and vertebral trabecular bone in normal individuals. Bone (1985) 0.99
Influence of hyper- and hypothyroidism, and the effects of treatment with antithyroid drugs and levothyroxine on fracture risk. Calcif Tissue Int (2005) 0.99
Effects of PTH(1-84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial. Osteoporos Int (2014) 0.99
Cortical bone mass, composition, and mechanical properties in female rats in relation to age, long-term ovariectomy, and estrogen substitution. Calcif Tissue Int (1993) 0.98
A model of vertebral trabecular bone architecture and its mechanical properties. Bone (1990) 0.98
Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism. Clin Endocrinol (Oxf) (2007) 0.98
Growth hormone stimulates proliferation and differentiation of normal human osteoblast-like cells in vitro. Calcif Tissue Int (1993) 0.97
Reconstruction of the resorptive site in iliac trabecular bone: a kinetic model for bone resorption in 20 normal individuals. Metab Bone Dis Relat Res (1984) 0.97
Estimation of the three-dimensional wall thickness of completed remodeling sites in iliac trabecular bone. Metab Bone Dis Relat Res (1982) 0.97
Age- and gender-related differences in vertebral bone mass, density, and strength. J Bone Miner Res (1999) 0.97
Primary hyperparathyroidism: short-term changes in bone remodeling and bone mineral density following parathyroidectomy. Bone (1999) 0.96
The positive effects of zinc on skeletal strength in growing rats. Bone (2001) 0.96
Reduced fracture risk in users of thiazide diuretics. Calcif Tissue Int (2005) 0.96
Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene. Osteoporos Int (2010) 0.96
Osteon cross-sectional size in the iliac crest: variation in normals and patients with osteoporosis, hyperparathyroidism, acromegaly, hypothyroidism and treated epilepsia. Acta Pathol Microbiol Immunol Scand A (1982) 0.96
Estimation of bone turnover evaluated by 47Ca-kinetics. Efficiency of serum bone gamma-carboxyglutamic acid-containing protein, serum alkaline phosphatase, and urinary hydroxyproline excretion. J Clin Invest (1985) 0.96
A tetracycline-based histomorphometric evaluation of bone resorption and bone turnover in hyperthyroidism and hyperparathyroidism. Acta Med Scand (1978) 0.96
Biochemical evidence of disturbed bone metabolism and calcium homeostasis in two types of autosomal dominant osteopetrosis. Acta Med Scand (1988) 0.96
Predicting human vertebral bone strength by vertebral static histomorphometry. Bone (2002) 0.95